Advicenne S.A. (FRA:3MM)

Germany · Delayed Price · Currency is EUR

0.6170

+0.0040 (0.65%)

Last updated: Oct 23, 2026, 3:25 PM CEST

Market Cap	9.19M -61.1%
Revenue (ttm)	10.74M +82.1%
Net Income	43.00K
EPS	n/a
Shares Out	n/a
PE Ratio	213.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51
Open	0.6130
Previous Close	0.6130
Day's Range	0.6130 - 0.6170
52-Week Range	0.5910 - 2.2000
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 18, 2026

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Par... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2007

Employees 11

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 3MM

Financial Performance

In 2025, Advicenne's revenue was 6.40 million, an increase of 21.56% compared to the previous year's 5.27 million. Losses were -9.53 million, 47.5% more than in 2024.

Financial Statements